• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Precision BioSciences Inc.

    2/5/24 4:49:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DTIL alert in real time by email
    SC 13G 1 d125241sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

     

    Precision BioSciences, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.000005 per share

    (Title of Class of Securities)

     

     

     

    74019P108

    (CUSIP Number)

     

     

     

    January 24, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)

     

    ýRule 13d-1(c)

     

    oRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 pages 
     

     

    CUSIP No. 74019P108

     

    13G Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

     
    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨

    (b) ý

    3

    SEC Use Only

     

     

     
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of

    Shares

    BENEFICIALLY
    Owned by

    Each Reporting
    Person with

    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    6,400,000

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    6,400,000 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    6,400,000 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.2% 

    12

    type of reporting person

     

    pN 

     

     Page 2 of 8 pages 
     

     

    CUSIP No. 74019P108

     

    13G Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

     
    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨

    (b) ý

    3

    SEC Use Only

     

     

     
    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    Shares

    BENEFICIALLY
    Owned by

    Each Reporting
    Person with

    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    6,400,000

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    6,400,000 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    6,400,000 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.2% 

    12

    type of reporting person

     

    OO 

     

     Page 3 of 8 pages 
     

     

    CUSIP No. 74019P108

     

    13G Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

     
    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨

    (b) ý

    3 SEC Use Only

     

     

     
    4

    Citizenship or Place of Organization

     

    united states

     

    Number of

    Shares

    BENEFICIALLY
    Owned by

    Each Reporting
    Person with

    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    6,400,000

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    6,400,000 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    6,400,000 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.2% 

    12

    type of reporting person

     

    IN 

     

     Page 4 of 8 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Precision BioSciences, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    302 East Pettigrew Street, Suite A-100, Durham, NC 27701

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.000005 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number 74019P108

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 6,400,000 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 6,400,000 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 6,400,000 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 pages 
     

     

    The percentages used herein are based on 121,918,830 shares of Common Stock outstanding as of November 27, 2023, as set forth in the Issuer’s Proxy Statement filed on Schedule 14A that was filed with the Securities and Exchange Commission on December 4, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 5.2%
    Tang Capital Management 5.2%
    Kevin Tang 5.2%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 6,400,000 shares
    Tang Capital Management 6,400,000 shares
    Kevin Tang 6,400,000 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 6,400,000 shares
    Tang Capital Management 6,400,000 shares
    Kevin Tang 6,400,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 5, 2024  

     

     

    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 pages

     

     

     

    Get the next $DTIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DTIL

    DatePrice TargetRatingAnalyst
    1/10/2025$34.00Market Perform → Outperform
    BMO Capital Markets
    4/30/2024$19.00Buy
    Guggenheim
    6/17/2022$7.00Outperform
    BMO Capital Markets
    6/9/2022Outperform → Mkt Perform
    William Blair
    9/10/2021$23.00 → $26.00Buy
    Stifel
    More analyst ratings

    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Research Officer Smith J. Jefferson

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    6/3/26 4:06:39 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Kelly John Alexander

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    6/3/26 4:05:45 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by General Counsel and Secretary Scimeca Dario

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    6/3/26 4:06:16 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precision BioSciences upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00

    1/10/25 7:46:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Precision BioSciences with a new price target

    Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00

    4/30/24 6:25:20 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets initiated coverage on Precision BioSciences with a new price target

    BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00

    6/17/22 7:26:31 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    SEC Filings

    View All

    Precision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    5/27/26 7:30:35 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    5/26/26 5:20:29 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Precision BioSciences Inc.

    10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    5/5/26 7:20:04 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial

    First infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following administration of ECUR-506 Statistically significant reductions in the annualized rate of HAEs and hyperammonemic crises (HACs) observed in the completed low-dose cohort (n=3), with 57% (p =0.018) and 65% (p =0.011) reductions, respectively, in pre-dose to post-dose rates of events per person-year Data presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo t

    5/18/26 8:00:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

    – New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young as 2 years of age – – Greater efficacy with earlier intervention further differentiates PBGENE-DMD from microdystrophin approaches – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new preclinical data from its PBGENE-DMD pr

    5/14/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting

    Preliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data cutoff date. HACs are defined as plasma ammonia levels above 100µmol/L with neurologic status change. Data from these cohorts also demonstrate approximately 52% reduction in the annualized rate of HACs following ECUR-506 administration. HACs are the most clinically significant neurometabolic manifestation of ornithine transcarbamylase (OTC) deficiency. Reducing or preventing these crises is a key treatment goal, clinically meaningful measure of patient benefit, and an im

    5/13/26 6:00:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frankel Stanley bought $12,690 worth of shares (2,700 units at $4.70), increasing direct ownership by 16% to 19,478 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:01:09 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Brown Melinda bought $6,864 worth of shares (1,381 units at $4.97), increasing direct ownership by 6% to 23,346 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:00:53 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 4:50:29 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 4:00:06 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 1:34:42 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Leadership Updates

    Live Leadership Updates

    View All

    Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

    - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA

    8/1/24 7:15:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

    Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE

    6/20/24 7:00:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Appoints Melinda Brown to Board of Directors

    New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

    5/31/22 8:00:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DTIL
    Financials

    Live finance-specific insights

    View All

    Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more de

    4/30/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may en

    10/31/25 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care